However, known pro-proliferative, angiogenic, and anti-apoptotic properties of GH and insulin-like growth factor-I (IGF-I) (5) have raised concerns regarding the safety of GH replacement in patients with a history of treatment for cancer or non-malignant tumours and more generally in those at increased risk for malignancy development (6). This evidence concerns the gene GH1 and cancer.